One of Hal Barron's top drug prospects at GSK flunks a PhII test for rheumatoid arthritis, flailing in an intensely competitive field
One of GlaxoSmithKline’s $GSK top pipeline candidates has failed a Phase II trial — badly.
The pharma giant reported today that their anti-GM-CSF — GSK3196165, held up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
